Retinopathy News and Research

RSS

Patients with diabetes, hypertension more likely to develop open-angle glaucoma

Many Americans suffer from diabetes and hypertension and, according to a study by researchers at the University of Michigan Kellogg Eye Center, these individuals may have an increased risk of developing open-angle glaucoma.

18 Aug 2011

Patients with diabetes, depression more likely to develop serious eye disease

Patients with diabetes who also suffer from depression are more likely to develop a serious complication known as diabetic retinopathy, a disease that damages the eye's retina, a five-year study finds.

29 Jul 2011

Early detection critical in preventing vision loss among Baby Boomers

Probably the most worrisome health concern for Baby Boomers as they age is the increased possibility of visual impairment or vision loss. For this reason, early detection is critical in successfully preventing and treating eye conditions such as macular degeneration, cataracts, glaucoma and diabetic retinopathy, before they lead to major visual changes.

27 Jul 2011

New convenient device can track degenerative eye disease

An ophthalmologist at UT Southwestern Medical Center has helped create a convenient device that lets patients who have a degenerative eye disease better track vision changes.

27 Jul 2011

Novel drug delivery device can treat diabetes-related retinal damage

A team of engineers and scientists at the University of British Columbia has developed a device that can be implanted behind the eye for controlled and on-demand release of drugs to treat retinal damage caused by diabetes.

1 Jul 2011

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).

29 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

Wills Eye Institute and Thomas Jefferson University create new vision research center

A new vision research center based in Philadelphia will foster regional, national and global collaborations among a diverse group of exceptional clinicians and researchers working to better diagnose, treat and prevent visual diseases.

21 May 2011

Queen's University scientists partner to treat premature baby blindness with stem cells

Scientists from the School of Medicine, Dentistry and Biomedical Sciences at Queen's University Belfast are teaming up to develop a cure to an illness that can lead to blindness in premature babies, thanks to funding from children's charity Action Medical Research.

18 May 2011

Study demonstrates value of MicroPulse technology for diabetic macular edema treatment

IRIDEX Corporation today announced that leading clinicians have performed and published the results of a new study that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers, over the standard-of-care protocol for the treatment of eyes with diabetic macular edema.

5 May 2011

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME Study of ILUVIEN for the treatment of Diabetic Macular Edema at the 2011 ARVO Annual Meeting.

4 May 2011

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.

22 Apr 2011

Ketogenic diet may reverse impaired kidney function in diabetics

Researchers from Mount Sinai School of Medicine have for the first time determined that the ketogenic diet, a specialized high-fat, low carbohydrate diet, may reverse impaired kidney function in people with Type 1 and Type 2 diabetes. They also identified a previously unreported panel of genes associated with diabetes-related kidney failure, whose expression was reversed by the diet. The findings were published in the current issue of PLoS ONE.

21 Apr 2011

Study uses simulation model to assess cost-effective eye screenings for Americans with diabetes

Eye examinations every other year are more cost-effective than currently recommended annual eye exams for people with diabetes who are at low risk of diabetic retinopathy progression.

16 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

Diabetes management accepted for coverage by Chemical Abstracts

Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.

24 Mar 2011

NIH: Diabetic retinopathy leads to vision loss in working-age Americans

Diabetes is often called the "silent killer" because people who have it are often unaware they are affected. According to the American Diabetes Association, diabetes affects 26 million people – including children – in the United States. Approximately one-quarter of those people do not know they're living with the disease.

23 Mar 2011

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

11 Mar 2011

Statin drug may help prevent blindness in diabetics

New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes.

17 Feb 2011